FDA Panel to Convene on Bisphosphonate Drugs

By Rheingold Giuffra Ruffo & Plotkin LLP

The FDA has announced that a panel will convene on September 9, 2011 at the University of Maryland University College (UMUC) to discuss the growing literature and safety issues surrounding all bone drugs (i.e. Actonel, Boniva, Fosamax and alendronate). These drugs, known as bisphosphonates, have been associated with two serious side effects- osteonecrosis of the jaw (dead bone in the jaw) and femur fractures. Both serious injuries, have spawned a surge in litigation. The FDA will try to determine whether these injuries are a result of long-term bisphosphonate use, among other things. The results of this meeting could be very important to the current litigation in New York and New Jersey.

At Rheingold, Giuffra, Ruffo & Plotkin LLP, we believe the public arena is also an important and effective platform to fight for the victims of unbridled corporate greed and failed government regulation. We are seeking clients with compelling stories who wish to testify before this committee should we be invited to provide that testimony.

Related Posts